Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.

p15(INK4b) gene is an inhibitor of cyclin-dependent kinase (CDK) 4 and CDK6 whose expression is induced by transforming growth factor (TGF)beta. Recent reports suggest frequent methylation of the p15(INK4b) gene promoter in leukemias, and it has been proposed that this methylation could be necessary for leukemic cells to escape TGF beta regulation. We investigated the methylation status of p15(INK4b) gene in 53 myelodysplastic syndromes (MDS) cases, including nine that had progressed to acute myeloid leukemia (AML), using a recently described sensitive method where polymerase chain reaction (PCR) is preceded by bisulfite modification of DNA (methylation specific PCR). p15(INK4b) methylation was observed in 20 of 53 (38%) of the cases. Twenty of the 24 patients with greater than 10% bone marrow blasts had p15(INK4b) methylation (including all nine patients who had progressed to AML) as compared with none of MDS patients with <10% bone marrow blasts. No correlation between karyotypic abnormalities and methylation status was found. Patients with p15(INK4b) methylation had a worse prognosis, but the prognostic significance of p15(INK4b) methylation was no more found by multivariate analysis, due to its strong correlation to the percentage of marrow blasts. In 10 MDS cases, sequential DNA samples were available. In five of them, methylation of the p15(INK4b) gene was detected at leukemic transformation, but not at diagnosis. Our results showed that methylation of the p15(INK4b) gene in MDS is correlated with blastic bone marrow involvement and increases with disease evolution toward AML. It suggests that proliferation of leukemic cells might require an escape of regulation of the G1 phase of the cell cycle, and possibly of TGF beta inhibitory effect.

[1]  近藤 征史.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57[KIP2] gene at 11p15.5 , 1998 .

[2]  T. Kinoshita,et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997, Blood.

[3]  P. Yaswen,et al.  Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells , 1997, Molecular and cellular biology.

[4]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[5]  A. Reeve,et al.  Human p57KIP2 defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour , 1997, Oncogene.

[6]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. , 1997, Leukemia research.

[7]  J. Benítez,et al.  Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin’s lymphoma , 1997, Leukemia.

[8]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[9]  M. Link,et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.

[10]  J. Massagué,et al.  The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. , 1997, Genes & development.

[11]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[12]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Ruscetti,et al.  Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. , 1996, Blood.

[14]  C. Declercq,et al.  Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.

[15]  S. Elledge,et al.  Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. , 1996, Oncogene.

[16]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[17]  M. Dhodapkar,et al.  Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. , 1995, Leukemia research.

[18]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[19]  J. Griffin,et al.  Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. , 1995, Oncogene.

[20]  B. Quesnel,et al.  p16 gene homozygous deletions in acute lymphoblastic leukemia. , 1995, Blood.

[21]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[22]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[23]  G. Hannon,et al.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.

[24]  B. Quesnel,et al.  p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. , 1994, Blood.

[25]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[26]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[27]  A. Palotie,et al.  Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. , 1993, Leukemia.

[28]  R. Berger,et al.  Mutations in the p53 gene in myelodysplastic syndromes. , 1991, Oncogene.

[29]  Yunis Jj,et al.  Mechanisms of ras mutation in myelodysplastic syndrome. , 1989 .

[30]  J. Bos,et al.  Mechanisms of ras mutation in myelodysplastic syndrome. , 1989, Oncogene.